Japan approves Novo Nordisk ’ s once-weekly Type II diabetes drug

The Japanese Ministry of Health, Labor and Welfare gave Novo Nordisk (NYSE:NVO) the green light to market its once-weekly type II diabetes drug, Ozempic, Reuters reported today.
The pharma company’s drug, semaglutide, is a glucagon-like peptide-1 analog that mimics an intestinal hormone to trigger insulin production in people with diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Japan approves Novo Nordisk’s once-weekly Type II diabetes drug appeared first on MassDevice.

Source: Mass Device - March 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Eli Lilly & Co. Novo Nordisk Source Type: news